Marion Tanguy

Marion Tanguy

Auto-generated profile, based on publicly available information

Marion Tanguy

Université Paris-Cité, Inserm, Centre de recherche sur l'inflammation, UMR 1149, Paris, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2019 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
EBEmilie M. Bonnaud
Emilie M. Bonnaud
CTCécile Troupin
Cécile Troupin
Laurent DacheuxLaurent Dacheux
Laurent Dacheux
EHEdward Holmes
Edward Holmes
EMElodie Monchatre-Leroy
Elodie Monchatre-Leroy
HBHervé Bourhy
Hervé Bourhy
The development of high-throughput genome sequencing enables accurate measurements of levels of sub-consensus intra-host virus genetic diversity and analysis of the role played by natural selection during cross-species transmission. We analysed the natural and experimental evolution of rabies virus (RABV), an important example of a virus that is able to make multiple host jumps. In particular, we (i) analyzed RABV evolution during experimental host switching with the goal of identifying possible genetic markers of host adaptation, (ii) compared the mutational changes observed during passage with those observed in natura, and (iii) determined whether the colonization of new hosts or tissues requires adaptive evolution in the virus. To address these aims, animal infection models (dog and fox) and primary cell culture models (embryo brain cells of dog and fox) were developed and viral variation was studied in detail through deep genome sequencing. Our analysis revealed a strong unidirectional host evolutionary effect, as dog-adapted rabies virus was able to replicate in fox and fox cells relatively easily, while dogs or neuronal dog cells were not easily susceptible to fox adapted-RABV. This suggests that dog RABV may be able to adapt to some hosts more easily than other host variants, or that when RABV switched from dogs to red foxes it lost its ability to adapt easily to other species. Although no difference in patterns of mutation variation between different host organs was observed, mutations were common following both in vitro and in vivo passage. However, only a small number of these mutations also appeared in natura, suggesting that adaptation during successful cross-species virus transmission is a complex, multifactorial evolutionary process. Understanding the mechanisms that underpin the cross-species transmission and host adaptation of rabies virus (RABV) remains an important part of the ongoing goal to reduce and eliminate rabies. We utilized next-generation sequencing to perform a deep comparative analysis of the genomic evolution of RABV subpopulations during host adaptation in culture and in animals, with the aim of determining the molecular mechanisms involved in the host-species or tissue adaptation of rabies virus. In particular, we aimed to determine whether experimental evolution can recapitulate evolution in nature. Our results suggest that a limited number of mutations that appeared following both in vitro and in vivo passage were observed in natura. This study also suggests that dog RABV may be able to adapt to some hosts more easily than other host variants.

10 June 2023 in Journal of Hepatology
Verified
Journal Article
Closed access
LELaure Elkrief
Laure Elkrief
NGNathalie Ganne-Carrié
Nathalie Ganne-Carrié
HMHana Manceau
Hana Manceau
MTMarion Tanguy
Marion Tanguy
SVShantha Ram Valainathan
Shantha Ram Valainathan
PRPierre-Emmanuel Rautou
Pierre-Emmanuel Rautou

10 June 2025 in JHEP Reports
Verified
Journal Article
Open access
TRTeresa Rubio-Tomás
Teresa Rubio-Tomás
DMDavid Martí-Aguado
David Martí-Aguado
DBDelia Blaya
Delia Blaya
SASilvia Ariño
Silvia Ariño
BABeatriz Aguilar-Bravo
Beatriz Aguilar-Bravo
PSPau Sancho-Bru
Pau Sancho-Bru
Cellular senescence is characterized by the loss of proliferative capacity, cell cycle arrest, and the acquisition of a proinflammatory senescence-associated secretory phenotype (SASP). Senescence is frequently present in advanced chronic liver diseases; however, the impact of hepatocellular senescence in alcohol-associated liver disease (ALD) progression and alcohol-associated hepatitis (AH) is poorly understood. Senescence was evaluated in transcriptomic data from patients at different ALD stages: advanced fibrosis (n = 10), cirrhosis (n = 10), and AH (n = 29). Plasma GDF15 levels were tested in patients with AH (n = 68), compensated cirrhosis (n = 15), heavy drinkers without liver disease (n = 15), and healthy controls (n = 10). Results were confirmed in an independent validation cohort. Transcriptomic analysis revealed an increased expression of senescence-associated genes and an enrichment of SASP gene signatures in patients with cirrhosis and particularly with AH. The association of senescence with AH was confirmed by p21 staining and the expression of senescence markers (i.e. CDKN1A, CDKN2A, CDKN2B, IL6, and SERPINE1), which positively correlated with clinical severity scores. Among the SASP factors, GDF15 was expressed in the hepatocytes of patients with AH and was strongly associated with senescence markers. Circulating GDF15 levels were specifically increased in patients with AH and positively correlated with severity scores. Moreover, plasma GDF15 levels predicted the response to corticosteroids and 90-day mortality in two independent cohorts of patients with AH. These results suggest that AH is characterized by the presence of hepatocellular senescence and elevated circulating levels of SASP factors, particularly GDF15, which correlates with patients’ poor outcomes. This suggests that senescence may be both a player in AH pathogenesis and a potential biomarker for AH. The pathogenesis of alcohol-associated liver disease (ALD) and hepatitis (AH) remains to be fully elucidated, and there is a need for biomarkers that can effectively monitor disease progression and assess patient response to therapy. In this study, we show the association of AH with hepatocellular senescence and the hepatic expression of senescence-associated secretory phenotype (SASP) factors, which correlate with poor patient outcome. Furthermore, we provide evidence that SASP factors such as GDF15 may be potential plasma biomarkers for AH. The findings of this study lay the groundwork for future research into the role of senescence in the pathogenesis of AH, as well as into the potential use of senescence and SASP-related molecules as biomarkers for AH.

1 May 2018 in Journal of Hepatology
Verified
Journal Article
Closed access
JPJohanne Poisson
Johanne Poisson
MHMoira B. Hilscher
Moira B. Hilscher
MTMarion Tanguy
Marion Tanguy
AHAdel Hammoutene
Adel Hammoutene
CBChantal M. Boulanger
Chantal M. Boulanger
PRPierre-Emmanuel Rautou
Pierre-Emmanuel Rautou

20 December 2024 in JHEP Reports
Verified
Journal Article
Open access
SSSabrina Sidali
Sabrina Sidali
YSYlang Spaes
Ylang Spaes
KHKinan El Husseini
Kinan El Husseini
OGOdile Goria
Odile Goria
VMVincent Mallet
Vincent Mallet
PRPierre-Emmanuel Rautou
Pierre-Emmanuel Rautou
Porto-sinusoidal vascular disorder (PSVD) is a rare cause of portal hypertension. Data on hepatopulmonary syndrome (HPS) in PSVD are limited. This study aimed to determine the associated factors, plasma mediators, and evolution of HPS in patients with PSVD. Multicenter observational study of patients with PSVD with signs of portal hypertension in whom contrast-enhanced transthoracic echocardiography (CE-TTE) was performed. Among 196 patients with PSVD who underwent CE-TTE in 17 centers, 14 (7% [95% confidence interval 3–11%]) had a confirmed diagnosis of HPS. Patients with HPS more frequently had a genetic disorder associated with PSVD (50% vs. 6%, p <0.001), especially telomere biology disorders (p <0.001). Liver function was less preserved in patients with HPS, because they had lower prothrombin index (63% vs. 86%, p = 0.04), higher serum total bilirubin (37 μmol/L vs. 14 μmol/L, p <0.001), and lower serum albumin (32 g/L vs. 38 g/L, p <0.001). HPS tended to be associated with more portal venule obliterations (p = 0.085) and with nodular liver architecture (p = 0.069). Plasma concentrations of Angiopoietin-2, ICAM3, and Tie2 were higher in patients with HPS (p = 0.02, p = 0.04, p = 0.01, respectively). Out of the 14 patients with HPS, five underwent liver transplantation after a median follow-up of 34 months. Overall cumulative incidence of liver-related events and of death was similar between patients with and without HPS, when considering liver transplantation for HPS as a competing risk. HPS in patients with PSVD was associated with genetic disorders, less preserved liver function, and higher plasma concentrations of angiogenic mediators. When applying HPS model for end-stage liver disease exception policy for liver transplantation, overall survival of patients with PSVD and HPS was similar to that of patients with PSVD without HPS. Hepatopulmonary syndrome (HPS) is a rare complication of porto-sinusoidal vascular disorder (PSVD). This multicentric study found that patients with PSVD and HPS had less preserved liver function, and harbored genetic disorders more frequently (especially telomere biology disorders) than patients without HPS. HPS did not negatively impact transplantation-free survival when applying HPS MELD exception policy for liver transplantation through a competitive risk analysis. Our findings suggest that patients with PSVD with respiratory symptoms and/or telomere biology disorders may benefit from systematic screening for HPS.

26 August 2025 in JHEP Reports
Verified
Journal Article
Open access
ARAlix Riescher-Tuczkiewicz
Alix Riescher-Tuczkiewicz
SLStéphane Loyau
Stéphane Loyau
LVLaurence Venisse
Laurence Venisse
MTMarion Tanguy
Marion Tanguy
AWAntoine Wawrzyniak
Antoine Wawrzyniak
PRPierre-Emmanuel Rautou
Pierre-Emmanuel Rautou
The role of protease nexin 1 (PN-1), a serine protease inhibitor that regulates both coagulation and fibrinolysis, is unknown in patients with cirrhosis. This study aimed to provide a comprehensive assessment of the role of PN-1 in cirrhosis. Plasma PN-1 concentration in 212 patients with advanced chronic liver disease and 30 healthy individuals was measured by ELISA. The role of PN-1 was investigated using thrombin generation assay, rotational thromboelastometry, and clot lysis assay in platelet-rich plasma and platelet-free plasma from 10 patients with stable decompensated cirrhosis and 10 healthy individuals. Plasma PN-1 concentration was higher in patients with advanced chronic liver disease than in healthy individuals (0.21 vs. 0 ng/ml, p = 0.0001), strongly increased with liver disease severity and portal hypertension, and was associated with 1-year mortality. In patients with stable decompensated cirrhosis, the synergy between platelet PN-1 and thrombomodulin to inhibit thrombin generation, observed in healthy individuals, was lost. Importantly, platelet PN-1 inhibition induced a much greater acceleration of fibrinolysis in patients with cirrhosis than in healthy individuals (1.6 and 2.8 times greater reduction in lysis onset time and lysis index 30, respectively, without tPA). Unlike platelet PN-1, plasma PN-1 plays a negligible role in coagulation and fibrinolysis. Platelet-derived PN-1 was found to markedly limit fibrinolysis in decompensated cirrhosis, although its impact on coagulation appeared minimal. Although elevated plasma PN-1 concentrations were observed in patients with advanced chronic liver disease, they did not contribute to hemostasis regulation. Overall, PN-1 should be added to the list of hemostasis factors that are dysregulated in cirrhosis. The role of PN-1, a serpin that regulates both coagulation and fibrinolysis, is unknown in cirrhosis. PN-1 appears as an important regulator of fibrinolysis in patients with cirrhosis. The role of PN-1 (and platelets more broadly) should be taken into account when assessing fibrinolysis in patients with cirrhosis.